CANAKINUMAB clinical trials

A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)

This study is looking at new treatments for advanced lung cancer. It combines standard chemotherapy with a drug called pembrolizumab, sometimes adding another drug called canakinumab, to see if this mix is more effective and safe for patients.